Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 60/100

Failure Rate

33.3%

1 terminated/withdrawn out of 3 trials

Success Rate

66.7%

-19.8% vs industry average

Late-Stage Pipeline

33%

1 trials in Phase 3/4

Results Transparency

50%

1 of 2 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

N/A
1(50.0%)
Phase 3
1(50.0%)
2Total
N/A(1)
Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT02526004Not ApplicableCompleted

Cystic Fibrosis Microbiome-determined Antibiotic Therapy Trial in Exacerbations: Results Stratified

Role: collaborator

NCT02210221Completed

CENTER-TBI: Collaborative European NeuroTrauma Effectiveness Research in TBI

Role: collaborator

NCT01482559Phase 3Terminated

Management of Hypotension In the Preterm Infant

Role: collaborator

All 3 trials loaded